For US Healthcare Professionals
I am a:
Sign-up Portal
Explore coverage options in your area
Collected in 03/25 and subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.
Source: Managed Markets Insight & Technology, LLCTM, a trademark of MMIT, as of March 2025.
*Within 2% of the access being stated.
†These percentages may not represent 100% of formulary lives due to data limitations.
‡“Superior” means the number of first-line covered lives is at least 10% greater for TREMFYA® than for Cosentyx® (secukinumab), Taltz® (ixekizumab) and Humira® (adalimumab).
§The information provided does not imply comparable safety or efficacy between products and only represents access information. Indicated trademarks are the registered trademarks of their respective owners. Please refer to each product’s prescribing information for indication(s), recommended dosing, and administration.
II“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.
¶“Majority” means 51%-65% number of covered lives.
IN ADULTS WITH MODERATE TO SEVERE PLAQUE PsO
